Background: The Kappa variant is designated as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of interest (VOI). We identified 195 Kappa variant cases in a region of British Columbia, Canada-the largest published cluster in North America. Objectives: To describe the epidemiology of the Kappa variant in relation to other circulating SARS-CoV-2 variants of concern (VOC) in the region to determine if the epidemiology of the Kappa variant supports a VOI or VOC status. Methods: Clinical specimens testing positive for SARS-CoV-2 collected between March 10 and May 2, 2021, were screened for the detection of known circulating VOCs; approximately 50% of specimens were subsequently selected for whole genome sequencing (WGS). Epidemiological analysis was performed comparing the characteristics of Kappa cases to the main circulating variants in the region (Alpha and Gamma) and to non-VOC/VOI cases. Results: A total of 2,079 coronavirus disease 2019 (COVID-19) cases were reported in the region during the study period, of which 54% were selected for WGS. The 1,131 sequenced cases were categorized into Kappa, Alpha, Gamma and non-VOC/VOI. While Alpha and Gamma cases were found to have a significantly higher attack rate among household contacts compared to non-VOI/VOC cases, Kappa was not. Conclusion: Epidemiological analysis supports the designation of Kappa as a VOI and not a VOC. The Alpha and Gamma variants were found to be more transmissible, explaining their subsequent dominance in the region and the rapid disappearance of the Kappa variant. Variant surveillance strategies should focus on both detection of established VOCs and detection of potential new VOCs.
Background: The Kappa variant is designated as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of interest (VOI). We identified 195 Kappa variant cases in a region of British Columbia, Canada-the largest published cluster in North America. Objectives: To describe the epidemiology of the Kappa variant in relation to other circulating SARS-CoV-2 variants of concern (VOC) in the region to determine if the epidemiology of the Kappa variant supports a VOI or VOC status. Methods: Clinical specimens testing positive for SARS-CoV-2 collected between March 10 and May 2, 2021, were screened for the detection of known circulating VOCs; approximately 50% of specimens were subsequently selected for whole genome sequencing (WGS). Epidemiological analysis was performed comparing the characteristics of Kappa cases to the main circulating variants in the region (Alpha and Gamma) and to non-VOC/VOI cases. Results: A total of 2,079 coronavirus disease 2019 (COVID-19) cases were reported in the region during the study period, of which 54% were selected for WGS. The 1,131 sequenced cases were categorized into Kappa, Alpha, Gamma and non-VOC/VOI. While Alpha and Gamma cases were found to have a significantly higher attack rate among household contacts compared to non-VOI/VOC cases, Kappa was not. Conclusion: Epidemiological analysis supports the designation of Kappa as a VOI and not a VOC. The Alpha and Gamma variants were found to be more transmissible, explaining their subsequent dominance in the region and the rapid disappearance of the Kappa variant. Variant surveillance strategies should focus on both detection of established VOCs and detection of potential new VOCs.
Entities:
Keywords:
COVID-19; Kappa variant; SARS-CoV-2; variant of concern; variant of interest; variant surveillance
Authors: Andrew Rambaut; Edward C Holmes; Áine O'Toole; Verity Hill; John T McCrone; Christopher Ruis; Louis du Plessis; Oliver G Pybus Journal: Nat Microbiol Date: 2020-07-15 Impact factor: 17.745
Authors: Catherine A Hogan; Agatha N Jassem; Hind Sbihi; Yayuk Joffres; John R Tyson; Kyle Noftall; Marsha Taylor; Tracy Lee; Chris Fjell; Amanda Wilmer; John Galbraith; Marc G Romney; Bonnie Henry; Mel Krajden; Eleni Galanis; Natalie Prystajecky; Linda M N Hoang Journal: Emerg Infect Dis Date: 2021-08-13 Impact factor: 6.883
Authors: Summer E Galloway; Prabasaj Paul; Duncan R MacCannell; Michael A Johansson; John T Brooks; Adam MacNeil; Rachel B Slayton; Suxiang Tong; Benjamin J Silk; Gregory L Armstrong; Matthew Biggerstaff; Vivien G Dugan Journal: MMWR Morb Mortal Wkly Rep Date: 2021-01-22 Impact factor: 17.586
Authors: Chang Liu; Helen M Ginn; Wanwisa Dejnirattisai; Piyada Supasa; Beibei Wang; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Daming Zhou; Alexander J Mentzer; Yuguang Zhao; Helen M E Duyvesteyn; César López-Camacho; Jose Slon-Campos; Thomas S Walter; Donal Skelly; Sile Ann Johnson; Thomas G Ritter; Chris Mason; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M Siqueira; Christina Dold; Nigel Temperton; Tao Dong; Andrew J Pollard; Julian C Knight; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah C Gilbert; Tariq Malik; Miles W Carroll; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Vicky Baillie; Natali Serafin; Zanele Ditse; Kelly Da Silva; Neil G Paterson; Mark A Williams; David R Hall; Shabir Madhi; Marta C Nunes; Philip Goulder; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton Journal: Cell Date: 2021-06-17 Impact factor: 41.582